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 Abstract 
Background: Dementia with Lewy Bodies (DLB) is the second most common form of dementia 
in the elderly but has been overshadowed in the research field, due in part, to similarities 
between DLB, Parkinson's (PD) and Alzheimer’s diseases (AD). This overlap complicates 
clinical care in that an accurate diagnosis is not always straightforward, and suggests that these 
diseases may share common aetiology. We have recently shown that loci implicated in 
susceptibility to PD and AD also play a role in DLB and that the proportion of genetic correlation 
between these diseases is very similar, when the major risk locus, APOE, is excluded. These 
results demonstrate that not only is DLB related to these more common diseases from a purely 
genetic perspective, but also, that DLB has a strong and quantifiable genetic component. 
Methods: Here we have performed the first large-scale genome-wide association study of DLB 
in a combined cohort of 6,197 samples. We exploited the recently established Haplotype 
Reference Consortium panel as the basis for imputation to a total of 8.4 million high-quality 
imputed genotypes and performed independent replication and a meta-analysis of significant 
and suggestive results. 
Findings: Results confirm previously reported associations (APOE, SNCA, GBA) and provide 
genome-wide significant signals for two novel loci (BCL7C/STX1B and CNTN1), in addition to 
several loci with suggestive levels of association. Additionally, using the genome-wide SNP data 
we estimate the heritable component of DLB to be approximately 36%. 
Interpretation: These results allow us to start to characterize, for the first time, the role of 
common genomic variability in DLB. They show unequivocally that common genetic variability 
plays a role in this disease, that this variability is, to some extent, shared with PD and AD and 
suggest a unique genetic risk profile in this disease. 
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 Introduction 
Dementia with Lewy Bodies (DLB) is the second most common form of dementia 
following Alzheimer’s disease (AD) 1. Despite this fact, very little attention has been devoted to 
understanding the pathogenesis of this disorder, particularly when compared with the other 
common neurodegenerative diseases, AD and Parkinson’s disease (PD). 
So far, no single high penetrant genetic variant has been identified and replicated as a 
specific cause of DLB, either in families or population-based series. Three major factors may 
have contributed to this: first, DLB, a disease of old age, is not commonly seen in multiplex 
kindreds, meaning that successful linkage studies have been rare 2; second, the accurate 
clinical diagnosis of DLB is complex, with a relatively high rate of misdiagnosis 3; and third, 
because even the largest cohorts of DLB samples have been generally small, in many cases 
including less than 100 patients. However, it is currently indisputable that DLB has a strong 
genetic component. The epsilon-4 allele of APOE 4,5 is recognized to be a strong risk factor, as 
are heterozygous mutations and common polymorphisms in the glucocerebrosidase gene 
(GBA)6. Both of these results have stemmed from candidate gene association studies; it was 
known that APOE was strongly associated with AD and GBA was a strong risk factor for 
PD/Lewy body disorders. In addition to these genetic associations with susceptibility, we have 
recently shown that DLB has a significant heritable component 7. 
It has been shown that there is no overlap in common genetic risk between PD and AD 
8. A fact that is not entirely surprising given the obvious differences in phenotype. However, it is 
reasonable to hypothesize that the overlaps and differences in clinical and pathological 
presentation between DLB with both PD and AD stem, at least in part, from aspects in their 
underlying genetic architecture and, consequently, disease pathobiology. Specific genes/loci 
associated with disease as well as strength of association are factors that can be expected to 
modulate these phenotypic overlaps and differences. However, despite these encouraging 
findings, large-scale unbiased genetic studies in DLB have not yet been performed, which is 
likely due to the difficulty in identifying large, homogeneous cohorts of cases. 
To address the need for more powerful and comprehensive genetic studies of DLB, we 
performed the first large-scale genome-wide association study in this disease, using a total of 
1,743 cases and 5,033 controls. The majority of cases (n=1,324) were neuropathologically 
assessed, greatly improving diagnostic accuracy. Controls used were derived from two publicly 
available datasets and from the Mayo Clinic Florida control database. We performed imputation 
using the most recent imputation panel provided by the Haplotype Reference Consortium 
enabling us to have a detailed overview of common and intermediate frequency genetic 
variability. 
 
Methods 
Participants 
All case subjects (n=1,743) were diagnosed according to the consensus criteria for 
either clinical or pathological diagnosis of DLB 9. The majority of cases were pathologically 
diagnosed (n=1,324). Cases were included only when the likelihood of a diagnosis of DLB was 
“Intermediate” or “High”. Control subjects (n=5,033) are part of the “General Research Use” 
controls from the two studies publicly available at dbGaP (The Genetic Architecture of Smoking 
and Smoking Cessation (phs000404.v1.p1) and Genetic Analysis of Psoriasis and Psoriatic 
Arthritis (phs000982.v1.p1)) and the Mayo Clinic Florida control database. 
 
Discovery stage genotyping and quality control 
Case subjects (n=1,687) were genotyped in either Illumina Omni2.5M or Illumina 
OmniExpress genotyping arrays (n=987 and n=700, respectively) (Table 1). Controls (n=4,370) 
were genotyped in either Illumina Omni2.5M or Illumina Omni1M arrays (n=1,523 and n=2,847 
respectively). Autosomal variants with 
GenTrain scores >0.7 were included 
in the QC stage. We removed SNPs 
with a call rate <95%, HWE p-value in 
controls <1×10−7, or a minor allele 
frequency (MAF) <0.01. Samples 
were removed if they had substantial 
non-European admixture, were 
duplicates or first- or second-degree 
relatives of other samples, had a 
genotype call rate <98% or had 
substantial cryptic relatedness scores 
(PI_HAT >0.1). 
Population outliers were determined by principal components analysis (PCA), using 
SNPs passing the aforementioned quality-control filters. After LD-based pruning with version 1.9 
of PLINK 10 to quasi-independence (variance inflation factor =2), 130,715 SNPs remained in the 
Table 1: Characteristics of the DLB discovery cohort of DLB. N: 
number of samples; M:F: ratio of males to females. * Represents 
age at death, which was available for these cohorts. These 
values were not used for calculation of the complete mean age 
at onset. 
dataset. Genotypes for these SNPs were combined with 1000Genomes phase 3 genotypes for 
samples from the YRI, CEU, JPT, and CHB reference populations, and subjected to Principal 
Components Analysis (PCA). Individuals lying farther than ¼ of the distance between CEU and 
JPT/CHB/YRI when plotted on the first two PCA axes were considered to have substantial non-
European admixture and were excluded. 
 
Imputation 
We performed imputation using the most recent reference panels provided by the 
Haplotype Reference Consortium (HRC v1.1 2016). Eagle v2.3 was used to pre-phase 
haplotypes based on genotype data11,12. Imputation was conducted using the Michigan 
Imputation Server13. Following imputation, variants passing a standard imputation quality 
threshold (R2 >= 0.3) were kept for further analysis. 
 
Association tests 
We used logistic regression as implemented in PLINK210 to test for association of 
variants with the binary case-control phenotype. To control for population stratification, we used 
coordinates from the top twenty PCA dimensions as covariates in the regression model. We 
utilized QQ plots and the genomic inflation factor (λ) to test for residual effects of population 
stratification not fully controlled for by the inclusion of PCA and cohort covariates in the 
regression model. A meta-analysis of stage 1 and 2 was conducted with GWAMA14 using 
estimates of the allelic odds ratio and 95% confidence intervals. Gene-wise burden tests were 
performed using all variants with an effect in protein sequence and a maximum MAF of 5%, 
using SKAT-O 15,16 as implemented in EPACTS 17.  
 
Replication genotyping 
A total of 527 cases and 663 controls from the Mayo Clinic were included in the 
replication stage (Table 2). Replication was attempted for top variants showing a p-value in 
discovery of less than 1x10-6. A total of 32 signals were tested for replication using a Sequenom 
MassARRAY iPLEX SNP panel. 
Association in replication was tested 
using logistic regression models 
adjusted for age (age at onset for 
the clinically diagnosed DLB 
patients, age at death for the high likelihood DLB patients, and age at study for controls) and 
Table 2: Characteristics of the replication cohort. a Denotes age 
at examination for controls. 
gender. 
 
Phenotypic variance explained 
To estimate the phenotypic variance explained by the genotyped SNPs in this cohort we 
used GREML analysis as implemented in GCTA 18,19. We used the first ten principal 
components as covariates and a disease prevalence of 0.1% 20. We have also estimated the 
partitioned heritability by chromosome, where a separate genetic relationship matrix was 
generated for each chromosome. Each matrix was then run in a separate REML analysis. 
 
Results 
Single variant analysis 
Application of quality control filters to the dataset yielded high-quality genotypes at 
448,155 SNPs for 1,216 cases and 3,791 controls. After imputation and quality control, 
genotypes for 8,410,718 variants were available for downstream analyses. QQ plot and 
genomic inflation factor (λ=1) indicated good control of population stratification (Supplementary 
Figure 1). 
Five regions were associated at genome-wide significance (p<5x10-8) (Figure 1; Table 
3).  
 
 
Figure 1: Manhattan plot showing genome-wide p-values of association. The p-values were obtained by logistic 
regression analysis using the first 20 principal components as covariates. The y-axis shows −log10 p-values of 
8,410,718 SNPs, and the x-axis shows their chromosomal positions. The y-axis was truncated at p-value of 1x10-25. 
Horizontal red and green dotted lines represent the thresholds of p= 5x10-8 for Bonferroni significance and 
p=1x10−6 for selecting SNPs for replication, respectively. 
These included the previously described loci APOE (rs429358, OR=2.4, p=5.31x10-50), 
SNCA (rs7681440, OR=0.7412, p=1.45x10-9) and GBA (rs35749011, OR=2.5, p=1.77x10-9). 
Additionally, loci overlapping BCL7C/STX1B (rs897984, OR=0.72, p=2.64x10-10) and GABRB3 
(rs1426210, OR=1.32, p=4.63x10-8) were also genome-wide significant. Two additional regions 
surpassed a suggestive threshold of significance (p=1x10−6), the first overlapping the SOX17 
gene (rs139919032, OR=2.4, p=1.37x10-7) and the second overlapping the CNTN1 gene 
(rs79329964, OR=1.5, p=4.35x10-7). Stage 2 of the GWAS design provided independent 
replication for 4 of the loci. The associations at GABRB3, BCL7C/STX1B and SOX17 were not 
replicated. However, meta-analysis of both stages showed the BCL7C/STX1B association to 
survive genome-wide multiple test correction (p=1.19x10-8; Table 3). 
 
 
Table 3: Top signals of association at each locus that passed genome-wide or suggestive thresholds for 
significance and their replication and meta-analysis p-values. CHR: Chromosome. R2: Imputation R-squared 
of each specific variant. OR: Odds ratio. L95: Lower 95% interval. U95: Upper 95% confidence interval. N: 
Total number of samples. Effects: direction of association 
 
The association observed at the SNCA locus represents an independent signal when 
compared to the top association reported for PD. In an attempt to dissect the differential 
association between the two diseases, we used 
GTEx data to try to determine if the top SNPs for 
each disease act as eQTLs. The most associated 
SNP in DLB is a strong eQTL in the cerebellum for 
RP11-67M1.1, a known antisense gene located at 
the 5’-end of SNCA, with the alternative allele 
showing a reduction in expression of RP11-67M1.1 
(Figure 2). These results are compatible with a 
model in which rs7681440 genotypes influence the 
expression levels of SNCA through the action of 
RP11-67M1.1. More specifically, the alternative 
allele associates with a lower expression of RP11-
67M1.1 and consequently less repression of SNCA 
Figure 2: Boxplot showing the association 
between rs7681440 genotypes and RP11-
67M1.1 expression in the cerebellum in 103 
healthy post-mortem samples (p=2.00E-07) 
from the GTEx Consortium. Carriers of the GG 
genotype (alternative allele) show the lowest 
levels of expression of the gene. Medians, 
interquartile ranges and individual data points 
are indicated. 
transcription (higher SNCA expression), which is in accordance with a higher frequency of the 
alternative allele in cases when compared to controls.  
A systematic assessment of genetic loci previously associated with AD or PD showed no 
evidence of other significant associations in this DLB cohort. This includes the TREM2 locus, 
where the p.R47H has been shown to have a strong effect in AD. In our cohort the p.R47H 
variant did not show genome-wide significant levels of association (p=0.002). 
 
Gene burden analysis 
Gene-wide burden based analysis of all low frequency (MAF < 0.05) and rare variants 
changing the amino acid sequence, showed a single genome-wide significant result comprised 
of 6 variants at GBA (p=1.29x10-13). No other gene showed evidence of strong association with 
disease or overlap with single variant analysis (Table 4).  
 
 
Table 4: Gene burden results, showing the most significant genes. NS: Number of samples with non-missing 
genotypes. FRAC_WITH_RARE : Fraction of individual carrying rare variants below the allele frequency 
threshold (0.05). NUM_ALL_VARS : Number of all variants defining the gene group. NUM_PASS_VARS : 
Number of variants passing the frequency and call-rate thresholds. NUM_SING_VARS : Number of singletons 
among variants in NUM_PASS_VARS. 
 
Estimation of heritability of DLB 
Using the first ten principal components as covariates and a disease prevalence of 0.1%, 
the estimation of the phenotypic variance attributed to genetic variants showed a heritable 
component of DLB of 36% (± 0.03). We have also partitioned the heritability across the genome, 
using each chromosome as a unit. We applied linear regression to determine the relationship 
between heritability and chromosome length. The results are presented in Figure 3. We found a 
strong correlation between chromosome length and heritability (Pearson correlation r = 0.745, 
p-value = 6.87x10-5). 
Interestingly the heritability 
at chromosome 19 is much higher 
than what would be expected given 
chromosome size and likely 
reflects the role of APOE. It should 
also be noted that chromosomes 5, 
6, 7 and 13 all have higher 
heritability than expected, while 
none of them have variants with 
genome-wide significant results. 
 
Discussion 
This is the first comprehensive unbiased study of common genetic variability in DLB. We 
identified five genome-wide significant associations (APOE, BCL7C/STX1B, SNCA, GBA, and, 
CNTN1), and two loci with suggestive levels of association in the discovery phase, that did not 
replicate in the smaller second stage (GABRB3 
and SOX17). In both of these cases the regions 
showed effect heterogeneity, suggesting that it is 
possible that a larger replication series would lead 
to a different outcome.  
The most significant association signal is 
observed at the APOE locus (APOE E4) which 
has been previously shown to be highly 
associated with DLB 4,5. As described APOE E4 
is the major genetic risk locus for AD and has 
been implicated in cognitive impairment within PD 
although not with PD risk per se. It has also been 
observed to affect the levels of both β-amyloid 
and Lewy body pathology in brains of patients 21.  
The second strongest association is observed at the SNCA locus and we were able to 
confirm the different association profile between DLB and PD that we had previously reported 5. 
SNCA is the most significant common genetic risk factor for PD, with rs356182 having a meta-
analysis p-value of 1.85x10-82 (OR:1.34 [1.30-1.38]) in PDGene. This variant is located 3’ to the 
gene 22, while in DLB no association can be found in that region (Figure 4). Additionally, the 
Figure 3: DLB heritability by chromosome. Heritability (y-axis) per 
chromosome is plotted against chromosome length (x-axis). The 
red line represents heritability regressed on chromosome length 
and the shaded grey area represents the 95% confidence interval 
of the regression model. 
Figure 4: Regional association plot for the SNCA 
locus. Purple represents rs1372517, which is the 
most associated SNP at the locus also present in 
the 1000Genomes dataset. The variant rs1372517 
is in complete LD with rs7681440. Colours 
represent LD derived from 1000Genomes 
between each variant and the most associated 
SNP. 
most associated SNP reported here for the SNCA locus (rs7681440) has a meta-analysis p-
value>0.05 in PDGene. Interestingly, when performing a conditional analysis on the top PD 
SNP (rs356182), Nalls and colleagues reported an independent association at the 5’ region of 
the gene (rs7681154, OR:0.841, p-value=7.09x10−19). It is tempting to speculate that these 
differences may reflect pathobiological differences between both diseases, perhaps mediated 
by differential regulation of gene expression. We show that the top DLB hit is an eQTL in the 
cerebellum for a SNCA antisense gene, however, further investigation of the identified 
significant eQTL is needed: the effect was observed for only one brain region, even though 
other regions are present in the GTEx dataset, many with similar sample sizes, and including 
regions preferentially affected by Lewy body pathology (substantia nigra, frontal cortex, 
caudate). Nonetheless, it is interesting to note that the effect fits with a model of increased 
SNCA expression in cases compared to controls. 
The top hit at the GBA locus (rs35682329) is located 85,781bp downstream of the gene 
and is in high LD (D’: 0.9; R2: 0.8) with p.Glu365Lys (also reported in the literature as E365K, 
E326K, rs2230288), which has been suggested as a risk factor for DLB 6. The top associated 
variant for PD at this locus is the rs71628662 
(PDGene meta-analysis OR:0.52 [0.46-0.58] and 
p-value 6.86x10-28). This variant is also in high LD 
with the top SNP identified here (D’: 0.9 and 
R2:0.8). Interestingly in this study we show that 
APOE and GBA have similar effect sizes in DLB 
(ORs of 2.5 and 2.2, respectively). 
 An association at the BCL7C/STX1B 
locus has been previously reported for PD 22,23. 
The top PD-associated variants at this locus were 
rs14235 (synonymous) and rs4889603 (intronic), 
located at BCKDK and SETD1A, respectively. The top SNP identified in DLB at this locus 
(rs897984) shows the same direction of association seen in PD (OR=0.93, 95%CI:0.90-0.96) 
and a meta-analysis p-value of 1.34x10-5 (data from PDgene). This is a gene-rich region of the 
genome (Figure 5) making it difficult to accurately nominate the gene driving the association. 
Mining data from the GTEx project showed that rs897984 is not an eQTL for any gene in the 
locus. Nonetheless, in both PD studies, the nominated gene at the locus was STX1B likely due 
to its function as a synaptic receptor 24. In addition, STX1B has a distinctive pattern of 
Figure 5: Regional association plot for the 
BCL7C/STX1B locus. Purple represents the 
most associated SNP. Colours represent LD 
derived from 1000Genomes between each 
variant and the most associated SNP. 
expression across tissues, presenting the highest expression in the brain. In this tissue, when 
compared to the closest genes in the locus (HSD3B7, BCL7C, ZNF668, MIR4519, CTF1, 
FBXL19, ORAI3, SETD1A, STX4), STX1B also shows the highest levels of expression 
(Supplementary Figure 3). Mutations in STX1B have recently been shown to cause fever 
associated epileptic syndromes 25 and myoclonic astatic epilepsy 26. 
The CNTN1 locus has been previously associated with PD in a genome-wide study of 
IBD segments in an Ashkenazi cohort 27, and with cerebral amyloid deposition, assessed with PET 
imaging in APOE E4 non-carriers 28. This locus was also shown to be sub-significantly associated 
with clinico-pathologic AD dementia 29. The Contactin 1 protein encoded by CNTN1 is a 
glycosylphosphatidylinositol (GPI)-anchored neuronal membrane protein that functions as a cell 
adhesion molecule with important roles in axonal function 30,31. Mutations in CNTN1 were found 
to cause a familial form of lethal congenital myopathy 32. Contactin 1 drives Notch signalling 
activation and modulates neuroinflammation events, possibly participating in the pathogenesis 
of Multiple Sclerosis and other inflammatory disorders 33. A functional protein association 
network analysis of CNTN1 using STRING shows it is in the same network as PSEN2 
(Supplementary Figure 4), supporting its potential role in neurodegeneration. However it is 
worth noting that LRRK2 is located less than 500kb away from the most associated SNP at this 
locus, which could suggest that the association might be driven by variation at the LRRK2 locus. 
We assessed LD across the region and that analysis revealed that rs79329964 is in equilibrium 
with both p.G2019S (R2: 0.000043) as well as with the PD hit at this locus rs76904798 (R2: 
0.003), suggesting it to be an independent association from the PD risk. Although samples were 
not screened for p.G2019S directly, the variant was well imputed (R2=0.94) and showed a 
higher frequency in cases when compared to controls (0.004 and 0.0005 respectively). 
In addition to performing a GWAS with clinico-pathologic AD dementia, Beecham and 
colleagues 29 also analysed commonly comorbid neuropathologic features observed in older 
individuals with dementia, including Lewy body disease (LBD). In this latter analysis, only the 
APOE locus was found to achieve genome-wide significance. However, when testing known 
common AD risk variants with coincident neuropathologic features, the authors identified hits at 
SORL1 and MEF2C as nominally associated. In our cohort of DLB cases we found no genome-
wide significant associations between these variants and disease. Similarly, we had previously 
reported a study-wide association at the SCARB2 locus with DLB 5. In the larger dataset studied 
herein, the association remained at the suggestive level and did not reach genome-wide 
significance (top SNP in the current study rs13141895: p-value=9.58x10−4). No other variant 
previously reported to be significantly associated with AD or PD in the recent GWAS meta-
analyses showed a genome-wide significant association with DLB. Variants at the following loci 
showed nominal association levels: MAPT, BIN1, GAK, HLA-DBQ, CD2AP, INPP5D, ECHDC3 
and SCIMP (Supplementary Table 1). 
Two loci (SOX17 and GABRB3) were significantly associated with DLB in the discovery 
phase, but these associations did not survive replication when analysing an independent, albeit 
smaller, cohort. However, it is interesting to note that mutations in GABRB3 have been 
associated with a broad phenotypic spectrum of epilepsies 34, similar to what has been reported 
for STX1B 25,26. Genetic variability at GABRB3 has also been reported to be significantly 
associated with hallucinations and delusions in cohorts of schizophrenia spectrum disorders 
35,36, traits that could be seen as having parallels in DLB. Even though this is the largest cohort 
of DLB cases studied so far in a genome-wide manner, it is only a moderately sized dataset, 
suggesting that it is plausible that the study of larger numbers of samples would provide enough 
statistical power to confidently identify variants such as these. 
This is the first large-scale genome-wide association study performed in DLB. We 
estimate the heritability of DLB to be approximately 36%, which is similar to what is known to 
occur in PD 37. This shows that, despite not having any causative genes identified so far, 
genetics plays a relevant role in the common forms of DLB. Additionally, we provide evidence 
suggesting that novel associated loci are likely to be found at chromosomes 5, 6, 7 and 13 given 
the high heritability estimates at these chromosomes. A significant majority of our case cohort in 
the current study was comprised of cases with neuropathological diagnoses. This greatly 
reduces the chances of misdiagnosis, and consequently improves power to detect associations, 
particularly when compared with clinical cohorts. These results provide us with the first glimpse 
into the molecular pathogenesis of DLB; they reveal that this disorder has a strong genetic 
component and a unique genetic risk profile. From a molecular perspective, DLB does not 
simply sit between PD and AD; instead, the combination of risk alleles is unique with loci that 
are strong risk factors for those diseases having no clear role in DLB (e.g. MCCC1, STK39, 
CLU, CR1 or PICALM). Further increases in the size of DLB cohorts will likely reveal additional 
common genetic risk loci, and these will, in turn, improve our understanding of this disease, its 
commonalities and differences with other neurodegenerative conditions, ultimately allowing us 
to identify disease-specific targets for future therapeutic approaches. 
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